At the 2026 Baiqiang Conference—widely regarded as the pharmaceutical retail industry’s premier annual event—the Hainan Jintai Pharmaceutical Group unveiled its flagship bone health brand, Liquean, at the Suzhou Longzhi Dream Convention Center on March 20, 2026. Positioned prominently in the exhibition’s central zone, Liquean showcased two evidence-informed, clinically aligned products: Liquean Calcium Carbonate D3 Tablets (I) and Liquean Glucosamine Sulfate Capsules—reinforcing a comprehensive, dual-target strategy for skeletal and joint health.
Liquean has established itself as a nationally recognized calcium supplementation brand grounded in the mission “Empowering Nationwide Calcium Optimization.” Since its inception, the brand has focused exclusively on musculoskeletal wellness, developing high-quality, science-backed formulations to support both bone mineral density and articular cartilage integrity. Its two cornerstone products are now distributed across all provinces in China and have become trusted partners for pharmacy chains nationwide—reflecting strong alignment with evolving retail pharmacy priorities centered on clinical service and patient education.
The conference, organized by China Pharmacy magazine—a publication under the supervision of China’s National Health Commission—is one of the most authoritative voices in the pharmaceutical retail sector. With coverage spanning over 90% of medium- and large-scale retail pharmacies, the magazine has spent more than two decades connecting stakeholders across government, academia, research, and industry. This year’s theme spotlighted a paradigm shift: from transactional, product-centric business models toward relationship-driven, service-oriented care ecosystems—where pharmacists serve as accessible health advisors rather than mere dispensers.
Liquean’s exhibition space embodied this ethos—featuring a clean, modern design in vibrant orange and crisp white that conveyed both scientific rigor and patient-centered warmth. Throughout the event, pharmacy buyers, chain executives, and clinical pharmacists engaged actively with Liquean representatives, drawn by the brand’s integrated approach to musculoskeletal health and its commitment to supporting frontline pharmacy practice through training, point-of-care tools, and consumer-facing educational resources.
This strategic emphasis is urgently warranted. According to the China Nutrition and Chronic Disease Report (2020), the average daily calcium intake among Chinese adults is just 328.3 mg—only 41% of the recommended dietary allowance. Concurrently, osteoarthritis prevalence exceeds 50% in adults aged 60 and older. These two conditions are pathophysiologically intertwined: age-related glucosamine depletion accelerates cartilage degradation, while chronic calcium and vitamin D insufficiency impairs bone remodeling and increases fracture risk. Bone (the “hard” structural scaffold) and cartilage (the “soft” load-bearing interface) function synergistically—and effective prevention requires coordinated intervention.
Liquean Calcium Carbonate D3 Tablets (I) deliver 600 mg of elemental calcium per tablet, co-formulated with 125 IU of cholecalciferol (vitamin D3). This combination enhances intestinal calcium absorption and supports bone mineralization—key for the prevention and adjunctive management of osteoporosis.
Liquean Glucosamine Sulfate Capsules provide pharmaceutical-grade glucosamine sulfate, a well-studied nutraceutical shown to modulate inflammatory pathways in synovial tissue, stimulate proteoglycan synthesis, and support structural repair of articular cartilage. The formulation is indicated for age-related joint degeneration, post-traumatic cartilage injury, and occupational overuse syndromes associated with prolonged static postures.
Together, these agents represent a biologically rational, complementary regimen: calcium and vitamin D fortify the bony matrix, while glucosamine sulfate nourishes the extracellular matrix of cartilage. This “hard bone–soft cartilage” dual-support framework addresses both structural integrity and functional mobility—offering a holistic, preventive, and patient-centered model for long-term musculoskeletal resilience.
“Empowering Nationwide Calcium Optimization” is more than a slogan—it reflects Liquean’s end-to-end commitment: from GMP-compliant manufacturing and bioavailability-optimized formulation, to pharmacist training programs and community-level nutrition literacy initiatives. In an era where retail pharmacies are redefining their role in public health, Liquean’s science-led, service-enabling approach offers a scalable blueprint for advancing musculoskeletal wellness—one consultation, one prescription, and one informed choice at a time.